The UK market for digital healthcare services has changed rapidly in recent years, particularly in the area of clinical weight management. Demand for GLP-1 medications such as Mounjaro and Wegovy has increased as more consumers seek medically supervised support for long-term weight management. Alongside this growth, online pharmacies and digital clinics have become more prominent in providing access to prescriptions, consultations, and ongoing patient support.
Curely, a Glasgow-based online pharmacy founded around late 2023, has emerged as one of the newer companies operating within this market. The company focuses heavily on GLP-1 weight-loss medications and has built its business around a subscription-based care model.
According to company figures, Curely reached approximately £1 million in monthly revenue during late 2025 and reported roughly £5 million in trailing 12-month revenue.
Focus on Subscription-Based Weight Management
Curely’s operating model centers on recurring subscriptions for GLP-1 medications, particularly Mounjaro, which contains tirzepatide as its active ingredient. The medication is administered via weekly injections and is commonly supplied in a monthly pen format.
The company positions its service around long-term treatment management rather than short-term purchasing. This includes online consultations, prescription management, delivery services, and dosage adjustments through a digital-first system.
Several features define Curely’s subscription structure:
- No cancellation fees or tie-in contracts
- Flexible dosage changes
- The ability to pause treatment when required
- Free delivery across the UK
- Secure online consultations without in-person appointments
The company states that this flexibility is designed to support patients who may require ongoing treatment adjustments over time.
Curely’s approach also reflects broader healthcare trends. NHS England recently noted that access to tirzepatide through NHS primary care settings will follow a phased rollout. According to the NHS England guidance, “there will be a phased approach to service rollout within primary care settings (for example, GP practices), and initially tirzepatide (Mounjaro®) will only be available on the NHS to those with the highest clinical need.”
This limited access within public healthcare has increased attention on regulated private providers operating in the UK market.
A Shift Toward “Lifestyle Optimization”
One of Curely’s more distinctive positioning strategies involves reframing GLP-1 medications away from narratives focused solely on morbid obesity. Instead, the company presents weight management as part of broader lifestyle optimization.
Its target demographic consists primarily of women aged 30 to 45 who are seeking support for weight management, physical health, and long-term wellness goals. The company suggests that many patients entering the market are not necessarily seeking emergency interventions but rather seeking structured clinical support to maintain activity levels and improve quality of life as they age.
This positioning reflects wider discussions within obesity management and preventative healthcare. Professor John P. H. Wilding, an obesity-management specialist and author of a 2018 review on weight management services, observed that “weight management services are inconsistently implemented.” He also noted that financial pressures and workload constraints have limited broader adoption of specialist services and anti-obesity medications.
Curely appears to position itself within this gap by combining regulated pharmaceutical access with digital convenience and ongoing patient interaction. The company also emphasizes patient education. Educational resources address practical concerns associated with medications like Mounjaro, including side effects, injection sites, dietary recommendations, and expected timelines for results.
Competitive Pricing Within a Price-Sensitive Market
Pricing has become a significant factor within the UK GLP-1 market. Treatments such as Mounjaro and Wegovy are often associated with long-term use, meaning affordability plays an important role in customer retention.
Curely has adopted an aggressive pricing strategy in response to this environment. Company materials indicate that the business intentionally positions itself below larger competitors in certain areas of the market.
The company reports that its pricing approach has supported rapid growth while maintaining an estimated customer lifetime value of approximately £1,200 per subscriber. Curely also reports an average order value of roughly £140 and a conversion rate near 4%.
Within this competitive landscape, regulated access has become increasingly important. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has repeatedly warned consumers about the risks of purchasing weight-loss medications through unregulated online sources or social media sellers.
According to the MHRA, “The MHRA continues to warn about the serious risks linked to buying weight-loss products from unregulated websites or through social media. Products sold illegally may be fake, contaminated, incorrectly dosed, or contain powerful ingredients not listed on the packaging.”
As a UK-registered online pharmacy, Curely positions itself as a regulated source of prescription GLP-1 medications in the UK market. The company also highlights its pharmacy registration credentials and Trustpilot rating to emphasize medical legitimacy and patient trust.
Building a Digital-First Patient Experience
Another major part of Curely’s strategy involves creating a streamlined digital experience for patients managing long-term prescriptions online.
The company has stated that it plans to expand its use of AI-driven customer service tools in the future. According to company materials, this includes developing AI-first support systems to improve responsiveness while maintaining personalized patient interactions.
This reflects a broader movement across digital healthcare, where companies increasingly rely on automation to manage growing patient demand while still offering individualized support.
Curely’s focus on customer experience also appears tied to its market positioning. Rather than competing solely on product access, the company emphasizes communication, convenience, and ongoing engagement throughout treatment.
The company has also received visibility through digital PR placements in publications including Forbes, MSN, and Men’s Health. While Curely does not publicly list formal industry awards, these placements have contributed to broader brand recognition within the UK healthcare and wellness sector.
Curely’s Position in the UK Weight-Loss Market
The online weight-management market in the UK continues to expand as consumer demand for GLP-1 medications grows. Curely has positioned itself in this sector through a combination of subscription-based care, competitive pricing, digital consultations, and a broader lifestyle-oriented narrative around weight management.
Its focus remains heavily concentrated on GLP-1 medications, which company leadership describes as the business’s primary growth priority. At the same time, Curely continues to maintain additional pharmaceutical categories to support a broader healthcare offering.
As access to medications like Mounjaro continues to evolve across both public and private healthcare systems, companies operating in this space are likely to face increasing scrutiny over pricing, regulation, patient safety, and clinical trust.
Curely’s current strategy suggests an effort to balance rapid digital growth with the expectations placed on regulated healthcare providers operating within the UK market.
